Kirkland & Ellis advised Slayback Pharma LLC on its sale to Azurity Pharmaceuticals Inc, which was announced September 27. The sellers included investment firm KKR and private equity firm Everstone Capital. Slayback is now a wholly-owned subsidiary of privately-held pharmaceutical company Azurity. Slayback focuses on complex generic and specialty pharmaceutical products.
The Kirkland team was led by corporate partners Neil Vohra, Andrew Arons and Jennifer Perkins and associates Lisa Gunter, Sophie Frishberg and Gino Jacobazzi; antitrust & competition partners Rich Cunningham and Samantha Morelli; tax partners Mike Beinus and Vivek Ratnam; debt finance partners Paul Rezvani and associates Ashley Martin and Negin Fatahi; and technology & IP transactions partners Daniel Lewis and Amber Harezlak.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
